Exegenesis Bio's EXG110 Receives Orphan Drug Designation from FDA for Fabry Disease Exegenesis Bio, a global clinical-stage gene therapy company, is thrilled to announce that the U.S.

www.linkedin.com/pulse/exegen...

Exegenesis Bio's EXG110 Receives Orphan Drug Designation from FDA for Fabry Disease

kstrategyand.com/pharma-news

#ExegenesisBio #EXG110 #OrphanDrugDesignation #FabryDisease #GeneTherapy #FDA #RareDiseases #BiotechInnovation #Humanteconomy #Humantech #KStrategyand